Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/40153
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Telomerase-driven expression of the sodium iodide symporter (NIS) for in vivo radioiodide treatment of cancer: A new broad-spectrum NIS-mediated antitumor approach |
Autor: | Riesco-Eizaguirre, Garcilaso CSIC ORCID; Vieja, Antonio de la CSIC ORCID; Rodríguez, Irene; Miranda, Soledad CSIC; Martín-Duque, Pilar; Vassaux, Georges; Santisteban, Pilar CSIC ORCID | Palabras clave: | Medullary-thyroid cancer Adenocarcinoma cell-line Targeted radiotherapy Reverse-transcriptase Transport defect Gene-expression Na/i symporter |
Fecha de publicación: | 1-sep-2011 | Editor: | Endocrine Society | Citación: | Journal of Clinical Endocrinology and Metabolism 96(9): E1435-E1443 (2011) | Resumen: | [Context]: Telomerase promoters (hTERT and hTR) are useful for transcriptional targeting in gene therapy models of cancer. Telomerase-driven expression of the sodium iodide symporter (NIS) in tumor cells has been successfully used as a reporter gene in vivo using positron emission tomography (PET) imaging. [Objective]: The aim of this study was to investigate the NIS-mediated therapeutic effect of telomerase promoters in a wide variety of human cancer cell lines. [Design and Methods]: Promoter fragments from either hTERT or hTR were used to drive the expression of NIS in cell lines derived from melanoma (M14), breast (MDA-MB-231), colon (HT-29), lung (H460), ovarian (OVCAR-3), and thyroid (TPC-1) carcinomas. Iodide uptake assays, protein immunodetection, and clonigenic assays were used to confirm NIS functional expression and the (131)I-mediated cytopathic effect. Tumor xenografts in mice were infected with hTERT and hTR and then treated using radioiodide. [Results]: Both promoters were selectively active in cancer cells that were effectively killed by exposure to (131)I. One single dose of 1 mCi (131)I markedly suppressed tumor growth of melanoma-derived tumor xenografts compared with controls. This effect was more modest in colon cancer-derived xenografts in part due to the reduced infectivity and the tumor cystic nature. The therapeutic effect of hTR promoter was found to be stronger than that of hTERT promoter. [Conclusions]: These results demonstrate that telomerase-driven expression of NIS could potentially have applications for 131I therapy of a wide variety of cancers. Additionally, this is the first study to report NIS-mediated 131I therapy of melanoma tumors in vivo. | Versión del editor: | http://dx.doi.org/10.1210/jc.2010-2373 | URI: | http://hdl.handle.net/10261/40153 | DOI: | 10.1210/jc.2010-2373 | ISSN: | 0021-972X |
Aparece en las colecciones: | (IIBM) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
accesoRestringido.pdf | 15,38 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
SCOPUSTM
Citations
22
checked on 10-mar-2024
WEB OF SCIENCETM
Citations
21
checked on 27-feb-2024
Page view(s)
322
checked on 18-mar-2024
Download(s)
46
checked on 18-mar-2024
Google ScholarTM
Check
Altmetric
Altmetric
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.